Non-Small Cell Lung Cancer (NSCLC)

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.

Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.

The FDA accepted a BLA for Dato-DXd based on data from the TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 trials.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.

Results from the phase 3 MARIPOSA trial found that amivantamab plus lazertinib met the final pre-specified secondary end point of overall survival in NSCLC.

The WU-KONG1 trial found that sunvozertinib yielded a best ORR of 53.3% and a cORR of 44.9% in patients with NSCLC harboring EGFR exon20ins mutations.

Findings from the phase 3 SACHI trial support the National Medical Products Administration’s priority review designation for savolitinib/osimertinib.

Although not hitting its primary end point, a phase 2 trial showed that SBRT plus concurrent radiotherapy improved on results elicited in other trials.

The decision is supported by results from the phase 2 TRUST-1 trial, which evaluated the safety and efficacy of taletrectinib in ROS1-positive NSCLC.

Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.

Feedback from the European Medicines Agency following results of the phase 3 TROPION-Lung01 informed the marketing authorization application withdrawal.

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.

The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.

A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.

The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.

A panel of experts review a case of a 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Taletrectinib demonstrated favorable efficacy and tolerability data in the TRUST-I and TRUST-II trials for the treatment of patients with advanced non–small cell lung cancer.

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.